UCB drags 15 firms to court for patent violation

UCB Inc,a Belgium-based global biopharmaceutical company focusing on central nervous system and immunology treatment and research,has filed separate patent infringement cases against as many as 15 drug makers at a court in Delaware

Written by ENS Economic Bureau | Hyderabad | Published: July 23, 2013 3:33 am

UCB Inc,a Belgium-based global biopharmaceutical company focusing on central nervous system and immunology treatment and research,has filed separate patent infringement cases against as many as 15 drug makers at a court in Delaware,US to prevent generic drug makers such as Ranbaxy,Aurobindo,Sun Pharma,Glenmark,Sandoz,,Watson,Alembic from entering the market with versions of its epilepsy treatment drug Vimpat.

Vimpat (Lacosamide) is indicated as an add-on therapy for the treatment of partial-onset seizures in adults with epilepsy. According to a petition filed by UCB Inc,UCB Pharma GmBH,Research Corporation Technologies Inc and Harris FRC Corporation,the patent of its lacosamide tablets would expire on March 17,2022.

The petitioners requested the court to issue a permanent injunction and enjoin the respondents from engaging in the commercial manufacture,offer to sell or import until the expiration of the patent,or any later date of exclusivity to which the petitioners are entitled.

For all the latest News Archive News, download Indian Express App

    Live Cricket Scores & Results